Loading clinical trials...

Adaptation of Written Exposure Therapy in Substance Treatment | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

Adaptation of Written Exposure Therapy in Substance Treatment

Treating OUD/PTSD in Residential Care: Written Exposure in Substance Treatment (WEST).

NCT07108608•Potomac Health Foundations

Summary

The purpose of this pilot non-randomized, uncontrolled clinical trial is to test the feasibility and efficacy of written exposure therapy (WET) for posttraumatic stress disorder (PTSD) as adapted for use within the context of residential substance use disorder (SUD) treatment. All participants meet criteria for PTSD and are in a short term residential SUD treatment program (target residential treatment duration = 28 days) regardless of the research. The main question the study aims to answer is: 1) Is the delivery of adapted WET feasible and acceptable in short term residential SUD treatment for individuals with severe SUD?

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Enrolled in residential SUD treatment at MTC
•Meet criteria for PTSD based on the Clinician-Administered PTSD Scale for DSM-5
•Be 18 years of age or older
•Have sufficient memory of the index trauma to write about it
•Be English speaking.

Exclusion Criteria

•Inability to give informed consent for any reason (e.g., cognitive impairment)
•Presence of acute psychosis or suicidality that would interfere with study participation
•planning to leave residential treatment before WEST could realistically be completed as determined by the investigator

Locations (1)

Maryland Treatment Centers

Baltimore, Maryland, United States

Key Dates

Start Date

August 25, 2025

Primary Completion Date

April 30, 2026

Completion Date

September 30, 2026

Last Updated

August 7, 2025

Enrollment

ESTIMATED participants

Conditions

Posttraumatic Stress DisorderSubstance Use Disorders

Interventions

Written Exposure Therapy

BEHAVIORAL

Treatment as Usual

BEHAVIORAL

Contacts

Rebecca Schacht, PhD

CONTACT

410.455.562 rschacht@umbc.edu

Kevin Wenzel, PhD

CONTACT

410.233.1400 kwenzel@marylandtreatment.org

Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)

NCT04197921

Opioid-use DisorderSubstance Use Disorders

View study

RECRUITINGNA

CIH Stepped Care for Co-occurring Chronic Pain and PTSD

NCT06219408

Chronic PainPosttraumatic Stress Disorder

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 7, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Adaptation of Written Exposure Therapy in Substance Treatment

Inclusion Criteria

Exclusion Criteria

Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)

CIH Stepped Care for Co-occurring Chronic Pain and PTSD

Augmenting Massed Cognitive Processing Therapy (CPT) to Prevent Suicide Risk Among Patients With PTSD

Temporal Interference Methods for Addiction Treatment

Improving Social Functioning in People With Substance Use and Mental Health Disorders Using VR

Ayahuasca, Esketamine and PTSD